Two Delayed Cancer Vaccine Readouts: Why I Am More Optimistic About AMPLIFY-7P Than REGAL
AMPLIFY-7P and REGAL both face delayed readouts as events accumulate slower than projected. A comparison of trial design, mechanistic evidence, and immune correlates, and why my conviction behind ELI-002 in PDAC and GPS in CR2 AML is not equal.